AxoGen (NASDAQ:AXGN) & Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Head to Head Comparison

AxoGen (NASDAQ:AXGN) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Profitability

This table compares AxoGen and Fresenius Medical Care AG & Co. KGaA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Fresenius Medical Care AG & Co. KGaA	5.03%	8.73%	4.02%

Analyst Recommendations

This is a summary of recent recommendations for AxoGen and Fresenius Medical Care AG & Co. KGaA, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	2	0	9	0	2.64
Fresenius Medical Care AG & Co. KGaA	4	6	0	0	1.60

AxoGen presently has a consensus price target of $46.50, indicating a potential upside of 7.44%. Fresenius Medical Care AG & Co. KGaA has a consensus price target of $28.00, indicating a potential upside of 24.47%. Given Fresenius Medical Care AG & Co. KGaA’s higher probable upside, analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than AxoGen.

Insider and Institutional Ownership

80.3% of AxoGen shares are held by institutional investors. Comparatively, 8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 2.8% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares AxoGen and Fresenius Medical Care AG & Co. KGaA”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21 million	10.22	-$15.70 million	($0.64)	-67.63
Fresenius Medical Care AG & Co. KGaA	$22.20 billion	0.57	$1.11 billion	$1.91	11.78

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

AxoGen has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

Summary

Fresenius Medical Care AG & Co. KGaA beats AxoGen on 8 of the 14 factors compared between the two stocks.

About AxoGen

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.